CRBN and plasma cell myeloma: A study reporting the effect of lenalidomide treatment on multiple myeloma patients indicated that PFS is significantly shorter in patients exhibiting low CRBN levels than in those exhibiting high CRBN levels (5.6 vs. 19.7 months) and a similar effect was observed for OS (11.4 vs. 30.5 months) (15).